The science

Vaginal dryness, painful sex, and recurrent UTIs are usually treated as separate problems. They are one problem.

This tissue was built by estrogen, and it needs estrogen to stay that way

The vulva, vagina, urethra, and bladder are dense with estrogen receptors. That is not incidental anatomy. Estrogen actively maintains this tissue, and it does several jobs at once.

It keeps the vaginal lining thick and multi-layered. It supports blood flow, which is what makes the tissue plump, pink, and capable of lubricating. It maintains elasticity and collagen, which is what allows the vaginal canal to stretch. And it drives the production of glycogen in the cells of the vaginal lining, which feeds the lactobacilli that dominate a healthy vaginal microbiome. Those bacteria produce lactic acid, and that acid holds vaginal pH in its normal range, roughly 3.8 to 4.5, acidic enough to discourage the organisms that cause infection.

Every one of those functions depends on estrogen being present.

When estrogen falls, the tissue changes

Estrogen declines through perimenopause and into menopause. It is suppressed during breastfeeding. It ends abruptly when both ovaries are removed. It is deliberately lowered by aromatase inhibitors, by GnRH therapy for endometriosis or fibroids, and by other antiestrogen treatments. It is low in primary ovarian insufficiency.

The cause differs. The tissue response does not.

The vaginal lining thins and loses its layers. Blood flow decreases. Elasticity and collagen are lost, and the canal becomes shorter and narrower. Glycogen production drops, so the lactobacilli lose their food supply, their numbers fall, and less lactic acid is produced. Vaginal pH rises above 5. As it does, the organisms that were previously held in check, including the E. coli that causes most urinary tract infections, are able to colonize far more easily.

The clinical name for the resulting condition is genitourinary syndrome of menopause, or GSM. It was formally adopted in 2014 to replace narrower terms like vulvovaginal atrophy, which described the vaginal tissue while ignoring the urinary tract entirely.[1]

Why a single treatment addresses symptoms that seem unrelated

Vaginal dryness, burning, itching, pain during sex, urinary urgency, and urinary tract infections that keep returning look like six different problems. Women are often treated for them separately, by different clinicians, over years.

They are one problem. Every symptom on that list traces back to the same tissue change, driven by the same hormone deficiency. That is why one treatment can address all of them, and it is the single most useful thing to understand about this condition.

It also explains why lubricants and vaginal moisturizers go only so far. They add moisture to the surface, which genuinely helps in the moment, and clinical guidelines specifically recommend them alongside other therapies. But they do not restore the lining, the blood flow, the elasticity, or the pH. They manage a symptom without addressing what produced it.

Why local delivery is the point

Estradiol is the primary estrogen the ovaries produce during a woman's reproductive years. The estradiol in prescription vaginal products is structurally identical to it.

Applied vaginally at low dose, it acts on the tissue where it is placed. It restores the epithelium, improves blood flow, and allows glycogen production and the lactobacilli that depend on it to recover, which brings pH back toward its normal range. Very little enters the bloodstream.

Because systemic exposure stays minimal, local vaginal estrogen is generally considered separately from systemic hormone therapy. A progestogen is not typically required alongside it, and it is often appropriate for women who do not want systemic hormones or cannot take them.

What the evidence actually says

Among the treatments available for this condition, local low-dose vaginal estrogen has the most robust evidence base. That is the conclusion of the 2025 AUA/SUFU/AUGS guideline on the genitourinary syndrome of menopause (GSM), the first comprehensive multi-society guideline on the condition, built on a systematic review conducted by the Minnesota Evidence-based Practice Center.[2]

The Menopause Society reached the same conclusion in its 2020 position statement, identifying low-dose vaginal estrogen as first-line therapy for moderate to severe GSM.[3] A separate 2022 guideline from the AUA, CUA, and SUFU recommends local low-dose vaginal estrogen specifically to reduce the risk of recurrent urinary tract infections in perimenopausal and postmenopausal women.[4]

Guidelines also note that no single formulation has been shown superior to the others. Cream, tablet, insert, and ring are all effective, and the choice among them should be made between a woman and her clinician based on her circumstances and her preference.

About the warnings you may remember

For years, low-dose vaginal estrogen products carried a boxed warning describing risks including cardiovascular disease, breast cancer, and dementia. Those risks were drawn from research on systemic hormone therapy, at doses far higher than local vaginal preparations deliver, and clinicians in this field argued for a long time that applying them to local products misrepresented the evidence.

In November 2025, the FDA moved to remove those boxed warnings from hormone therapy products containing estrogen, and The Menopause Society supported removal on low-dose vaginal estrogen specifically, noting that the warning had likely deterred women from a treatment that would have helped them[5,6]. Some safety information remains, appropriate to each formulation, and labeling updates reach packaging on each manufacturer's own schedule.

The reason this history matters is that it is very likely part of why no one offered you this treatment.

What it does not do, and what else exists

Local vaginal estrogen treats vaginal and urinary symptoms. It does not treat hot flashes, night sweats, sleep disturbance, or mood changes, which involve systemic hormone therapy and a different clinical conversation.

We think the evidence for local estradiol is strong. We also think you are entitled to know what the alternatives are.

References

1. Portman DJ, Gass ML; Vulvovaginal Atrophy Terminology Consensus Conference Panel. Genitourinary syndrome of menopause: new terminology for vulvovaginal atrophy from the International Society for the Study of Women's Sexual Health and the North American Menopause Society. Menopause. 2014;21(10):1063-1068.
2. The AUA/SUFU/AUGS Guideline on Genitourinary Syndrome of Menopause. J Urol. 2025;214(3):242-250.
3. The 2020 genitourinary syndrome of menopause position statement of The North American Menopause Society. Menopause. 2020;27(9):976-992.
4. Recurrent Uncomplicated Urinary Tract Infections in Women: AUA/CUA/SUFU Guideline (2022). J Urol. 2022;208(3):536-541.
5. HHS Advances Women's Health, Removes Misleading FDA Warnings on Hormone Replacement Therapy. US Food and Drug Administration press announcement. November 10, 2025.
6. The Menopause Society Comments on the FDA Announcement on Hormone Therapy. The Menopause Society press release. November 10, 2025.

This page is for general education and is not medical advice. Talk with a licensed clinician about your symptoms and what treatment is appropriate for you.